Company | Value | Change | %Change |
---|
The launch of Chlorpromazine Hydrochloride for Injection, USP (25mg/1mL and 50mg/2 mL vials) is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market.
In 2024, PCC launched the first-to-market generic of Edaravone IV Infusion, which followed the 2023 launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP to further enhance their wide portfolio of critical care products.
Also Read: Why are shares of Piramal Pharma up over 8% in a weak market?
Peter DeYoung, Chief Executive Officer, of Piramal Global Pharma said, “We are excited to launch Chlorpromazine Hydrochloride for Injection, USP,
which joins our growing US porƞolio of injectable products at Piramal Critical
Care.
It further complements our market-leading inhaled anaesthesia products, as we strive to deliver critical care solutions to patients and healthcare providers around the world.”
Shares of Piramal Pharma Ltd ended at ₹242.65, up by ₹1.50, or 0.62% on the BSE.
Also Read: Piramal Pharma shares surge 20% after management guides for doubling revenue by FY30